GLP-1 Agonists: The Complete Guide

Introduction

GLP-1 receptor agonists are, by almost any measure, the most consequential new drug class to emerge in the last two decades. Originally developed for type 2 diabetes, they have exploded into the mainstream as weight-loss medications -- Ozempic, Wegovy, Mounjaro, and Zepbound are now household names, discussed as casually at dinner parties as they are in endocrinology clinics. By 2025, GLP-1 prescriptions had become one of the fastest-growing categories in pharmaceutical history, and the World Health Organization added them to its Essential Medicines List for obesity.

But the story of GLP-1 agonists is far richer than the Ozempic hype cycle suggests. It begins with Gila monster venom in the Arizona desert, winds through decades of incretin biology, and now extends into research on addiction, Alzheimer's disease, liver fibrosis, kidney failure, and sleep apnea. The drugs themselves vary enormously -- from twice-daily injections to once-weekly shots to daily pills -- and the lived experience of taking them ranges from effortless appetite suppression to weeks of debilitating nausea.

This guide covers all of it: the pharmacology, the clinical trials, the side effects, what people on Reddit actually say about being on these drugs, and where the field is headed.

What Is GLP-1 and Why Does It Matter?

Glucagon-like peptide-1 (GLP-1) is a hormone produced by L-cells in the small intestine in response to food intake. It belongs to a family of hormones called incretins, which are responsible for what physiologists call the "incretin effect" -- the observation that oral glucose triggers a much larger insulin response than the same amount of glucose delivered intravenously. GLP-1 accounts for up to 70% of insulin secretion after a meal.

When you eat, GLP-1 does several things simultaneously:

• Stimulates insulin secretion from pancreatic beta cells, but only when blood glucose is elevated (this glucose-dependent mechanism is why GLP-1 drugs rarely cause hypoglycemia on their own)
• Suppresses glucagon release from pancreatic alpha cells, reducing the liver's glucose output
• Slows gastric emptying, keeping food in the stomach longer and contributing to satiety
• Acts on the brain, particularly the hypothalamus and brainstem appetite centers, to reduce hunger and increase the sensation of fullness
• May act on reward circuitry in the mesolimbic dopamine system, reducing the motivational drive toward food and potentially other rewarding stimuli

The problem with native GLP-1 is that it is destroyed almost immediately. The enzyme dipeptidyl peptidase-4 (DPP-4) degrades circulating GLP-1 within about 2 minutes. This is where pharmaceutical engineering comes in: GLP-1 receptor agonists are synthetic molecules designed to activate the same receptor but resist enzymatic breakdown, extending their activity from minutes to hours, days, or an entire week.

From Gila Monster Venom to Ozempic: The History

The origin story of GLP-1 drugs is one of the most improbable in modern pharmacology.

In 1992, Dr. John Eng, an endocrinologist at the Veterans Affairs Medical Center in the Bronx, was studying hormones in the venom of the Gila monster (Heloderma suspectum), a venomous lizard native to the southwestern United States and northwestern Mexico. Eng isolated a peptide he named exendin-4, which shared 53% of its amino acid sequence with human GLP-1. Crucially, exendin-4 was resistant to DPP-4 degradation, giving it a half-life measured in hours rather than minutes.

This discovery led directly to the development of exenatide, a synthetic version of exendin-4. The FDA approved exenatide (brand name Byetta) in April 2005, making it the first GLP-1 receptor agonist to reach the market. Byetta required twice-daily injections and produced modest weight loss as a side effect of its glucose-lowering action -- a hint of what was to come.

The timeline of major GLP-1 drug approvals tells the story of rapid pharmaceutical evolution:

Each generation brought improvements in efficacy, convenience, and tolerability. But the real inflection point came with semaglutide. Novo Nordisk's molecular engineering added two key modifications to the GLP-1 backbone: a fatty acid chain that promotes binding to albumin (slowing renal clearance) and an amino acid substitution that shields the molecule from DPP-4. The result was a drug with a half-life of approximately 7 days -- enabling once-weekly dosing -- and subcutaneous bioavailability of 89%.

How GLP-1 Agonists Work: Mechanism of Action

GLP-1 receptor agonists bind to and activate the GLP-1 receptor (GLP-1R), a G protein-coupled receptor expressed in multiple tissues. The downstream effects depend on where the receptor sits:

In the pancreas: GLP-1R activation on beta cells triggers glucose-dependent insulin secretion through cAMP-PKA and Epac2 signaling pathways. On alpha cells, it suppresses glucagon release. This dual action lowers blood glucose without the hypoglycemia risk associated with sulfonylureas or exogenous insulin.

In the gastrointestinal tract: GLP-1R activation slows gastric motility, delaying stomach emptying by 20-40%. This keeps food in the stomach longer, contributing to early satiety and reduced meal size. It also underlies the most common side effect -- nausea.

In the brain: GLP-1 receptors are densely expressed in the hypothalamic arcuate nucleus, the area postrema, and the nucleus tractus solitarius -- regions that regulate appetite, satiety, and nausea. GLP-1 agonists reduce activity in hunger-promoting AgRP neurons and enhance activity in satiety-promoting POMC neurons. Functional MRI studies have shown that semaglutide reduces neural responses to food cues in brain reward centers.

In the cardiovascular system: GLP-1R is expressed in cardiomyocytes, vascular endothelium, and smooth muscle. Activation appears to reduce inflammation, improve endothelial function, and decrease atherosclerotic plaque formation -- effects that translate into meaningful cardiovascular risk reduction in clinical trials.

Tirzepatide -- the dual agonist: Tirzepatide is not a pure GLP-1 agonist. It simultaneously activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP is the other major incretin hormone, and adding GIP receptor activation appears to enhance insulin sensitivity, increase fat oxidation, and produce greater weight loss than GLP-1 activation alone. Whether tirzepatide's superiority comes from GIP agonism, its specific GLP-1 binding profile, or the combination remains an active area of investigation.

The Major GLP-1 Drugs Compared

Not all GLP-1 agonists are equal. They differ in molecular structure, receptor selectivity, dosing frequency, route of administration, and clinical efficacy.

Semaglutide (Ozempic / Wegovy / Rybelsus)

Semaglutide is the most widely prescribed GLP-1 agonist and the one most people mean when they say "Ozempic." Developed by Novo Nordisk, it is available as a once-weekly subcutaneous injection (Ozempic for diabetes at doses up to 2mg; Wegovy for obesity at 2.4mg) and as a daily oral tablet (Rybelsus for diabetes at doses up to 14mg, with a 25mg obesity formulation in development).

The STEP trial program established semaglutide as a transformative obesity treatment. In STEP 1, participants with obesity (without diabetes) lost an average of 14.9% of their body weight over 68 weeks with semaglutide 2.4mg versus 2.4% with placebo. In STEP 8, semaglutide outperformed liraglutide 3.0mg, producing 15.8% weight loss versus 6.4%.

Key pharmacological properties:

• Half-life: ~7 days (enabling weekly dosing)
• Subcutaneous bioavailability: 89%
• Oral bioavailability: less than 1% (but sufficient due to high receptor potency; must be taken on an empty stomach with minimal water)
• Peak plasma concentration: 1-3 days after injection

Tirzepatide (Mounjaro / Zepbound)

Tirzepatide, developed by Eli Lilly, is the first dual GIP/GLP-1 receptor agonist. It consistently produces greater weight loss than semaglutide in clinical trials. In the SURMOUNT-1 trial, participants on the highest dose (15mg) lost an average of 22.5% of body weight over 72 weeks. In the head-to-head SURMOUNT-5 trial, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide 2.4mg.

The SURPASS program demonstrated its efficacy in type 2 diabetes, with tirzepatide producing significantly greater HbA1c reductions than semaglutide 1mg in the head-to-head SURPASS-2 trial. Up to 86% of patients achieved HbA1c below 7%, and nearly half achieved HbA1c below 5.7% -- essentially normal glucose levels.

Liraglutide (Victoza / Saxenda)

Liraglutide was the second GLP-1 agonist to market and the first approved specifically for weight management (as Saxenda, at 3.0mg daily). It produces more modest weight loss than semaglutide or tirzepatide -- typically 5-8% of body weight -- but has an extensive safety track record spanning over 15 years.

The LEADER trial demonstrated cardiovascular benefits in patients with type 2 diabetes, with a 13% reduction in major adverse cardiovascular events. Liraglutide's main drawback is its daily dosing requirement, which many patients find inconvenient compared to weekly alternatives.

Dulaglutide (Trulicity)

Dulaglutide is a once-weekly GLP-1 agonist developed by Eli Lilly, primarily used for type 2 diabetes. The REWIND trial showed a 12% reduction in major adverse cardiovascular events. Weight loss is moderate, typically 3-5% of body weight. Dulaglutide is notable for its pre-filled single-use pen design, which many patients find easier to use than other injectable options.

Exenatide (Byetta / Bydureon)

As the first GLP-1 agonist, exenatide holds historical significance but has been largely superseded by newer agents. The short-acting formulation (Byetta) requires twice-daily injections, and neither formulation matches the efficacy of semaglutide or tirzepatide for weight loss or glucose control. The EXSCEL trial showed a trend toward cardiovascular benefit that did not reach statistical significance.

Clinical Evidence: What the Trials Actually Show

Weight Loss

The weight loss data from major trials puts the progression in stark perspective:

These are population averages. Individual responses vary substantially -- some patients lose 25-30% of their body weight, while a meaningful minority (roughly 10-15%) are "non-responders" who lose less than 5%.

Cardiovascular Outcomes

The SELECT trial was the landmark cardiovascular outcomes trial for GLP-1 agonists in patients without diabetes. Among 17,604 overweight or obese adults with established cardiovascular disease (but without diabetes), semaglutide 2.4mg reduced the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% compared to placebo (hazard ratio 0.80). All-cause mortality was reduced by 19%.

This was a paradigm shift. Previous weight loss interventions -- from diets to bariatric surgery -- had not demonstrated such clear cardiovascular benefits in a randomized trial. The SELECT results helped cement GLP-1 agonists as cardiovascular protective agents, not just weight loss drugs.

Diabetes Outcomes

In type 2 diabetes, the efficacy data is equally compelling. The SUSTAIN trials showed semaglutide reducing HbA1c by 1.5-1.8 percentage points. The SURPASS program showed tirzepatide reducing HbA1c by up to 2.3 percentage points, with 86-92% of patients reaching the target of HbA1c below 7%.

Beyond Diabetes and Obesity

Recent trials have expanded the evidence base dramatically:

• Kidney disease: The FLOW trial showed semaglutide reduced the risk of kidney failure or kidney-related death by 24% in patients with type 2 diabetes and chronic kidney disease. All-cause mortality was 20% lower in the semaglutide group.
• Sleep apnea: The SURMOUNT-OSA trial demonstrated that tirzepatide reduced the apnea-hypopnea index (a measure of sleep apnea severity) by 51-59% in people with obesity and moderate-to-severe obstructive sleep apnea.
• Liver disease (MASH/NASH): In patients with metabolic dysfunction-associated steatohepatitis and moderate-to-severe liver fibrosis, tirzepatide resolved MASH without worsening fibrosis in 44-62% of participants. Semaglutide has shown similar liver benefits in its own trial program.
• Heart failure: The STEP-HFpEF trial showed semaglutide improved symptoms, exercise capacity, and quality of life in patients with obesity-related heart failure with preserved ejection fraction.

Side Effects and Safety Profile

GLP-1 agonists are generally well-tolerated, but they are not without side effects. Understanding the full safety profile is essential for anyone considering these medications.

Common Side Effects (Affecting 20-50% of Patients)

Gastrointestinal symptoms are by far the most frequent adverse effects. Nausea affects 40-50% of patients in the early weeks of treatment. Vomiting, diarrhea, and constipation are also common. These symptoms are a direct consequence of the drugs' mechanism of action -- delayed gastric emptying and central appetite suppression.

The good news: for most patients, GI symptoms are worst during dose escalation and improve significantly within 4-8 weeks. Gradual dose titration is the standard approach to minimize these effects. Eating smaller meals, avoiding fatty foods, and not lying down immediately after eating can help.

Less Common but Notable Side Effects

Injection site reactions affect about 5-10% of patients, typically mild redness or itching that resolves on its own.

Fatigue and headache are reported in 5-10% of patients, particularly during dose escalation.

Gallbladder issues are seen at elevated rates in clinical trials. Rapid weight loss from any cause increases gallstone risk, and GLP-1 agonists are no exception. The STEP trials reported cholelithiasis (gallstones) in about 1.5-2.5% of semaglutide patients versus 0.5% on placebo.

Serious but Rare Safety Concerns

Pancreatitis: All GLP-1 agonists carry a warning about acute pancreatitis. GLP-1 drugs can elevate amylase and lipase levels (typically less than 3-fold), and rare cases of acute pancreatitis have been reported. However, large meta-analyses have not established a clear causal relationship between GLP-1 agonists and pancreatitis. The current evidence suggests the risk is very low, but patients with a history of pancreatitis should exercise caution.

Thyroid cancer (medullary thyroid carcinoma): In rodent studies, GLP-1 agonists caused thyroid C-cell tumors. Liraglutide carries a black box warning about medullary thyroid carcinoma (MTC) risk. Semaglutide and tirzepatide carry similar warnings. However, large retrospective studies in humans have not confirmed an increased risk of thyroid cancer with semaglutide use. The concern remains theoretical, and patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 should not use these drugs.

Gastroparesis: By slowing gastric emptying, GLP-1 agonists can, in rare cases, cause severe delayed gastric emptying that mimics or exacerbates gastroparesis. This has led to concerns about intestinal obstruction and aspiration risk during anesthesia. Many anesthesiologists now recommend holding GLP-1 agonists before elective surgery.

"Ozempic Face" and Muscle Loss: The Body Composition Question

Two side effects have captured public attention more than any clinical trial endpoint: "Ozempic face" and muscle loss.

Ozempic Face

"Ozempic face" is a colloquial term describing the gaunt, hollowed facial appearance that can result from rapid weight loss on GLP-1 agonists. It is not unique to Ozempic or even to GLP-1 drugs -- any significant weight loss can cause facial volume depletion, particularly in older adults. The face loses subcutaneous fat, leading to more prominent cheekbones, deeper nasolabial folds, and sagging skin that has lost its underlying structural support.

The phenomenon has driven a surge in demand for facial fillers and fat grafting among GLP-1 users. Dermatologists and plastic surgeons have noted a new patient demographic: people who are thrilled with their body weight but distressed by their facial appearance.

Prevention strategies focus on slower weight loss (lower doses, gradual titration), adequate protein intake to minimize lean tissue loss, and sun protection to preserve skin elasticity.

Muscle Loss

This is the more medically significant concern. Weight loss from any cause typically involves loss of both fat mass and lean mass (primarily muscle). The question is the ratio.

The data here is somewhat conflicting. In the STEP 1 trial, DEXA scans showed that approximately 39% of the weight lost on semaglutide was lean mass -- similar to the proportion seen with caloric restriction alone. One literature review reported that up to 50% of weight lost from GLP-1 agonists may be non-fat mass in some populations.

For younger, otherwise healthy adults, this lean mass loss may be clinically insignificant. For older adults, it is a genuine concern. Sarcopenia (age-related muscle loss) is a major risk factor for falls, fractures, disability, and mortality. Losing additional muscle on top of age-related decline could theoretically worsen long-term outcomes, even as obesity-related risks improve.

The emerging consensus among clinicians is clear: resistance training and adequate protein intake (1.2-1.6g per kg of body weight daily) should be considered non-negotiable for anyone on GLP-1 therapy. The combination of GLP-1 agonists with structured exercise appears to preferentially preserve muscle while enhancing fat loss, though large randomized trials specifically testing this combination are still in progress.

Off-Label Uses: Addiction, Alzheimer's, and Beyond

Some of the most exciting GLP-1 research has nothing to do with diabetes or obesity.

Addiction

GLP-1 receptors are expressed in the brain's mesolimbic reward system -- the same circuits hijacked by addictive substances. Preclinical studies have shown that GLP-1 agonists reduce alcohol self-administration in rodents, prevent cue- and stress-induced relapse to heroin-seeking behavior, and decrease cocaine self-administration.

Human data is catching up. A 2025 clinical trial by Hendershot and colleagues reported that semaglutide reduced alcohol consumption in patients with alcohol use disorder, with effect sizes larger than those seen with naltrexone or acamprosate -- the current standard treatments. Anecdotal reports from patients on GLP-1 agonists for weight loss who spontaneously reduced their alcohol intake had already generated enormous interest.

The proposed mechanism centers on dopamine. GLP-1 receptor activation in the ventral tegmental area and nucleus accumbens appears to blunt the dopamine release triggered by addictive substances, reducing their rewarding properties. People on GLP-1 drugs often describe it not as "white-knuckling" their way through cravings, but as simply losing interest in drinking. As one Reddit user put it: "I can have a beer in front of me and just... not care about it. It is the strangest thing."

Research is expanding into opioid use disorder, nicotine addiction, and even behavioral addictions like gambling. Several randomized controlled trials are currently enrolling.

Alzheimer's Disease and Neurodegeneration

GLP-1 receptors are widely expressed in the brain, and preclinical data suggests these drugs may have neuroprotective properties. Animal studies have shown that GLP-1 agonists reduce amyloid plaque formation, decrease tau phosphorylation, reduce neuroinflammation, and improve cognitive performance.

The EVOKE trials, conducted by Novo Nordisk, are the largest clinical trials testing semaglutide in early Alzheimer's disease, involving approximately 1,800 participants. Preliminary results were expected in late 2025, with the field watching closely.

A large retrospective cohort study found that GLP-1 receptor agonist use was associated with a 70% reduced risk of dementia diagnosis, though observational data like this cannot prove causation. The Alzheimer's Association has identified GLP-1 agonists as one of the most promising emerging treatment avenues.

Other Emerging Indications

• PCOS (Polycystic Ovary Syndrome): GLP-1 agonists improve insulin sensitivity and may restore ovulatory function in women with PCOS-related infertility
• Parkinson's disease: The NeurGLP-1 trial is testing exenatide in Parkinson's, with preclinical data showing dopaminergic neuroprotection
• Peripheral artery disease: Cardiovascular benefits may extend to peripheral vascular outcomes

Community Experience: What Reddit and Forums Say

Clinical trials tell you what happens to populations. Reddit tells you what it feels like to be one person on the drug. The GLP-1 communities on Reddit (r/Ozempic, r/Semaglutide, r/tirzepatide, r/GLP1_Drugs) have become some of the most active health-related subreddits, with hundreds of thousands of members sharing experiences.

The "Food Noise" Phenomenon

The most commonly discussed experience is the reduction or elimination of "food noise" -- the constant background chatter of thoughts about food, next meals, cravings, and eating impulses that many people with obesity describe as a defining feature of their daily life.

Users describe it as revelatory. Posts like "I walked past a bakery and felt nothing" and "For the first time in my life, I can eat half a plate and just stop" are ubiquitous. Many users express grief alongside relief -- grief that they spent decades believing their inability to control eating was a moral failure, when it was a neurochemical one that a drug could fix in weeks.

Side Effect Reports

Reddit provides a less sanitized picture of side effects than clinical trials. Common themes include:

• Sulfur burps: Described as "the worst side effect nobody warns you about." Extremely foul-smelling belching that many users say is socially humiliating. One user reported it "ruined a date."
• Severe constipation: Some users report going 5-7 days without a bowel movement during dose escalation, requiring stool softeners or fiber supplements
• Fatigue and brain fog: Particularly during the first few weeks, many users describe profound tiredness that makes it difficult to work
• Nausea management: The community has developed extensive folk wisdom around managing nausea -- ginger chews, small frequent meals, avoiding fatty foods, staying hydrated
• "Ozempic face" anxiety: Numerous before/after photo threads document facial changes, with users debating whether the weight loss is "worth" the facial aging

Weight Regain Concerns

One of the most discussed topics is what happens when you stop. Clinical data from the STEP 1 extension trial showed that participants regained approximately two-thirds of their lost weight within one year of discontinuing semaglutide. Reddit discussions reflect this anxiety, with many users viewing GLP-1 agonists as a lifelong commitment rather than a temporary intervention.

Cost and Access Frustrations

Cost is a dominant theme. Before recent price reductions, many users reported paying $900-1,400 per month out of pocket. Insurance coverage remains inconsistent, with many plans covering GLP-1s for diabetes but not for obesity. The compounding pharmacy market emerged partly to fill this gap, with users sharing experiences with compounded semaglutide at $250-400 per month.

Cost, Access, and the Compounding Controversy

Pricing

GLP-1 agonists have been among the most expensive drugs in the world relative to their patient population. As of early 2026, key pricing benchmarks include:

In late 2025, a White House deal with Novo Nordisk cut GLP-1 prices for Medicare beneficiaries to $245 per month with a $50 copay. Novo Nordisk also dropped cash-pay prices to $349 per month, with new patients getting their first two months at lower doses for $199. These price cuts, while significant, still leave GLP-1 agonists out of reach for many patients globally.

The Compounding Controversy

Compounding pharmacies -- which create customized drug formulations -- became a flashpoint in the GLP-1 story. During nationwide shortages of semaglutide and tirzepatide in 2023-2024, compounding pharmacies were legally permitted to produce copies under FDA shortage provisions. A massive direct-to-consumer telehealth industry sprang up around compounded GLP-1s, offering them at $250-400 per month.

When the FDA declared the semaglutide shortage resolved in February 2025 and tirzepatide in December 2024, the legal basis for compounding evaporated. The FDA began enforcement actions against compounders who continued production, and Novo Nordisk filed lawsuits against several compounding pharmacies and telehealth platforms. Some compounders switched to semaglutide salt forms (arguing these were technically different molecules), leading to further regulatory and legal battles.

The compounding controversy exposed deep tensions in the American healthcare system: between pharmaceutical companies protecting their intellectual property and profit margins, patients who cannot afford branded drugs, and regulators trying to ensure drug safety without creating access barriers.

Global Access

Outside the United States, access varies enormously. In the UK, the NHS has begun covering semaglutide for obesity through specialist weight management services, but with strict eligibility criteria and long waitlists. In many low- and middle-income countries, GLP-1 agonists are simply unavailable or unaffordable. The WHO's December 2025 decision to add GLP-1 medicines to its obesity treatment guidelines was partly aimed at increasing global access, but the gap between recommendation and availability remains vast.

The Future of GLP-1s: What Comes Next

The GLP-1 pipeline is one of the most active in all of pharmaceutical development. Several next-generation drugs are in late-stage clinical trials or approaching approval.

Oral Semaglutide for Obesity

Novo Nordisk is seeking FDA approval for a 25mg oral semaglutide tablet for obesity, which would be the first oral GLP-1 indicated for chronic weight management. In clinical trials, oral semaglutide 25mg produced approximately 11-13% weight loss -- less than the injectable formulation but with the obvious advantage of being a pill rather than an injection. For patients who are needle-averse or prefer daily dosing, this represents a significant step forward.

Retatrutide (Eli Lilly)

Retatrutide is a triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. The glucagon receptor component is the key differentiator -- glucagon activation increases energy expenditure and promotes hepatic fat oxidation, potentially addressing the muscle loss concern by shifting weight loss more toward fat loss.

In phase 2 trials, retatrutide produced jaw-dropping weight loss of up to 24% of body weight at the highest doses over 48 weeks. Phase 3 results are expected in the second half of 2026. If the phase 2 results hold up, retatrutide could produce weight loss approaching that of bariatric surgery.

Survodutide (Boehringer Ingelheim / Zealand Pharma)

Survodutide is a dual GLP-1/glucagon receptor agonist being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH), the progressive form of fatty liver disease. In phase 2 trials, it produced 14.9% weight loss over 49 weeks and showed significant improvements in liver fibrosis. Phase 3 trials for both obesity and MASH are ongoing.

CagriSema (Novo Nordisk)

CagriSema combines semaglutide with cagrilintide, an amylin analog. Amylin is another pancreatic hormone that promotes satiety. The combination has shown 15-17% weight loss in just 20-32 weeks in early trials, with the hope that the dual mechanism will produce greater efficacy and more durable weight maintenance than semaglutide alone.

Orforglipron (Eli Lilly)

Orforglipron is a small-molecule oral GLP-1 agonist -- meaning it is not a peptide like semaglutide but a traditional small-molecule drug that can be manufactured more cheaply and does not require the special absorption-enhancing formulation of oral semaglutide. Phase 3 trial results are expected in 2026 and could transform the economics of GLP-1 therapy.

Maritide / Maridebart Cafraglutide (Amgen)

Amgen's entry into the GLP-1 field targets both the GLP-1 receptor and the GIP receptor. Phase 3 trials for obesity are enrolling, with FDA approval expected in 2028 or beyond. Amgen's manufacturing scale could add competitive pressure on pricing.

Practical Considerations

Who Should Consider GLP-1 Agonists?

Current FDA-approved indications include:

• Type 2 diabetes (multiple GLP-1 agonists approved)
• Obesity (BMI of 30 or greater) oroverweight (BMI of 27 or greater) with at least one weight-related comorbidity (Wegovy, Zepbound, Saxenda)
• Cardiovascular risk reduction in adults with established CVD and overweight/obesity (Wegovy)

Important Drug Interactions and Precautions

• GLP-1 agonists slow gastric emptying, which can affect the absorption of other oral medications. Timing of other drugs may need adjustment.
• They should not be used with other GLP-1-based therapies (including DPP-4 inhibitors, which work on the same pathway).
• Patients with a history of pancreatitis, medullary thyroid carcinoma, or MEN2 syndrome should not use these drugs.
• Pregnancy is a contraindication -- GLP-1 agonists should be discontinued at least 2 months before planned conception due to their long half-lives.
• Anesthesiologists increasingly recommend holding GLP-1 agonists before elective surgery due to gastroparesis and aspiration risk.

Starting and Titrating

All GLP-1 agonists use a slow dose-escalation protocol to minimize gastrointestinal side effects. For semaglutide, the typical schedule is:

• Weeks 1-4: 0.25mg weekly
• Weeks 5-8: 0.5mg weekly
• Weeks 9-12: 1.0mg weekly
• Weeks 13-16: 1.7mg weekly
• Week 17 onward: 2.4mg weekly (target dose for obesity)

Rushing titration is the single most common cause of severe nausea and treatment discontinuation.

The Bigger Picture

GLP-1 agonists have forced a reckoning with how we think about obesity. For decades, the dominant narrative was that obesity was primarily a behavioral problem -- a failure of willpower, discipline, or moral character. The dramatic efficacy of GLP-1 drugs has made it harder to sustain that narrative. If a single injection can reduce someone's food intake by 30-40%, the problem was clearly never just about willpower.

These drugs have also raised uncomfortable questions. If obesity is a chronic disease requiring lifelong medication (as the weight regain data suggests), what does that mean for healthcare costs when tens of millions of people qualify for treatment? If GLP-1 agonists reduce the desire for food, alcohol, and other pleasurable activities, what does that mean for our relationship with pleasure and reward? If they produce weight loss equivalent to surgery, will bariatric surgery become obsolete?

The answers are still emerging. What is clear is that GLP-1 receptor agonists represent a genuine therapeutic revolution -- not just for the conditions they treat, but for the questions they force us to ask about the biology of human behavior, the economics of healthcare, and the meaning of a drug that can fundamentally alter what you want.